News for MeiraGTx Holdings plc (MGTX)

MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson’s Disease, and xerostomia, with multiple assets in advanced clinical stages showing...

We recently published a list of Top 10 AI News Updates Taking Wall Street By Storm.

U.S. stocks traded lower midway through trading, with the S&P 500 falling more than 1% on Thursday. The Dow traded down 1.17% to 40,865.63 while the NASDAQ dip...

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII gained 13.9% to $28.87 after t...

New York-based Y-mAbs Therapeutics, Inc. (YMAB) is down over 26 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $

- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen N

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.

**media[565507]**

**media[546514]**

On December 31, 2024, Prosight Management, LP (Trades, Portfolio) executed a significant transaction involving Vincerx Pharma Inc (VINC), reducing its holdings

We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks.

MeiraGTX president sells shares worth $305,342

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where MeiraGTx Holdings plc (NASDAQ:MGTX) stands against the other gene...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

FDA grants RMAT status to MeiraGTx's xerostomia gene therapy

-RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition -

MeiraGTx Holdings plc sees a surge in stock after positive Parkinson's disease data and strategic partnerships, showing growth potential. Click for my MGTX update.

PR NewswireROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a gl